August 21, 2017 1:50 AM ET

Biotechnology

Company Overview of Miragen Therapeutics, Inc.

Company Overview

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. The company’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers. Its clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for microRNA-29, which is found at abnormally low levels in various pathologi...

6200 Lookout Road

Boulder, CO 80301

United States

Founded in 2006

55 Employees

Phone:

303-531-5952

Fax:

303-531-5094

Key Executives for Miragen Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $340.0K
Chief Financial Officer, Treasurer and Secretary
Age: 43
Total Annual Compensation: $259.8K
Compensation as of Fiscal Year 2015.

Miragen Therapeutics, Inc. Key Developments

Miragen Therapeutics, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017

Miragen Therapeutics, Inc. announces unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported total revenue was $718,000 compared with $1,115,000 a year ago. Loss from operation was $7,350,000 compared with $3,450,000 a year ago. Net loss was $7,312,000 compared with $3,524,000 a year ago. Basic and diluted loss per share was $0.34 compared with $5.88 a year ago. The $0.4 million decrease was due primarily to decreases in license fee and development related revenue under the Company’s collaboration agreement with Servier. For the six months, the company reported total revenue was $1,180,000 compared with $2,032,000 a year ago. Loss from operation was $14,289,000 compared with $6,991,000 a year ago. Net loss was $14,292,000 compared with $7,147,000 a year ago. Basic and diluted loss per share was $0.87 compared with $11.92 a year ago. Total net cash used in operating and investing activities was approximately $14.1 million for the first half of 2017.

Miragen Therapeutics, Inc. Announces Board Changes

On August 10, 2017, Kyle A. Lefkoff and John W. Creecy each resigned from Miragen Therapeutics, Inc.’s board of directors and all committees of the board of which each was a member immediately before such resignations. On August 10, 2017, the board unanimously voted to elect Jeffrey S. Hatfield and Christopher Bowden, M.D. to the board, effective immediately. The appointments of Mr. Hatfield and Dr. Bowden were made to fill the vacancies on the board created by the resignations of Kyle A. Lefkoff and John W. Creecy. Mr. Hatfield and Dr. Bowden were appointed to the board to serve until their successors are duly appointed and qualified or their earlier death, resignation or removal. The board has determined that each of Mr. Hatfield and Dr. Bowden is an independent director as defined in the listing rules of The NASDAQ Capital Market. Mr. Hatfield has been appointed to serve as a member of the Audit Committee of the Board. Mr. Hatfield currently serves as a director on the boards of aTyr Pharma, Inc. and InVivo Therapeutics Corp. and has previously served as a director of Ambit Biosciences Corporation before it was acquired by Daiichi Sankyo Company Ltd. He is an adjunct professor and is a dean’s advisory board member for Purdue University’s College of Pharmacy. Dr. Bowden has been appointed to the Compensation Committee of the Board. He is currently serves as the chief medical officer of Agios Pharmaceuticals, Inc. Prior to joining Agios, he served as vice president, product development oncology, franchise lead (Signaling Group) at Genentech, Inc.

Miragen Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference, Aug-15-2017 01:20 PM

Miragen Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference, Aug-15-2017 01:20 PM. Venue: Le Parker Meridien Hotel, 119 West 56th St., New York, New York, United States. Speakers: William Stuart Marshall, Co-Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 1, 2016
Signal Genetics, Inc.
Private Placement
October 31, 2016
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Miragen Therapeutics, Inc., please visit www.miragentherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.